Finnrick, an independent testing programme, publishes 29 assays for PureRawz: 13 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 16 did not. Most recent assay 3 Jun 2025.
PureRawz operates from US, listed by Finnrick as "Trading", has no storefront on record — Finnrick lists only a messaging or social contact. Source: Finnrick, https://www.finnrick.com/vendors/pure-rawz.
Research chemical supplier offering peptides, SARMs, and nootropics for research purposes.
PureRawz is listed as active. Research chemical supplier offering peptides, SARMs, and nootropics.
No independent third-party assay is on file for PureRawz, and its storefront did not respond when we last tried to read it. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Ipamorelin | 5 | 2 passed, 3 failed |
| BPC-157 | 4 | 2 passed, 2 failed |
| CJC-1295 | 4 | 0 passed, 4 failed |
| Melanotan II | 4 | 3 passed, 1 failed |
| Retatrutide | 4 | 2 passed, 2 failed |
| Semaglutide | 4 | 2 passed, 2 failed |
| Tirzepatide | 4 | 2 passed, 2 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Production country | United States |
| Vendor type | Research-use supplier |
| Payment methods | Credit Card, Cryptocurrency |
PureRawz is listed as active and we hold 29 Finnrick assays (13 passing, 16 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 29 assays for PureRawz: 13 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 16 did not. Most recent assay 3 Jun 2025.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: PureRx Peptides Review, Purity Peptides Review, Purus Peptides Review.